OncoMatch/Clinical Trials/NCT06235437
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
Is NCT06235437 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ASD141 for metastatic solid tumor.
Treatment: ASD141 — This is a Phase I study designed to evaluate if ASD141 is safe, tolerable, and efficacious in participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy, investigational or approved cancer therapy (e.g., chemotherapy, biologics, hormone)
Exception: within 2 weeks or 5 halflives (whichever is shorter) prior to the first dose of study treatment
Has had curative radiotherapy, investigational or approved cancer therapy (e.g., chemotherapy, biologics, hormone [e.g., tamoxifen, leuprolide]) within 2 weeks or 5 halflives (whichever is shorter) prior to the first dose of study treatment.
Cannot have received: investigational device
Exception: within 4 weeks prior to the first dose of study treatment
Has used an investigational device or has had major surgery within 4 weeks prior to the first dose of study treatment.
Cannot have received: CD11b inhibitor
Has received previous treatment with another agent targeting the CD11b receptor.
Lab requirements
Blood counts
Neutrophil Count (ANC) ≥ 1,500 /µL; Platelets ≥ 100,000 /µL; Hemoglobin ≥ 9 g/dL
Kidney function
estimated GFR (non-indexed) ≥ 50 mL/min
Liver function
Serum total bilirubin ≤ 1.5X ULN OR Direct bilirubin ≤ 1.5X ULN for subjects with total bilirubin levels > 1.5 ULN; ≤ 3X ULN for subjects with hepatoma or Gilbert's disease; AST and ALT ≤ 2.5X ULN OR ≤ 5X ULN for subjects with active liver metastases and primary hepatoma
Cardiac function
QTcF < 480 msec; INR ≤ 1.5X ULN; aPTT ≤ 1.5X ULN
adequate organ function as indicated by the following laboratory values. Hematological Neutrophil Count (ANC) ≥ 1,500 /µL (mm3) Platelets ≥ 100,000 /µL (mm3) Hemoglobin ≥ 9 g/dL Renal estimated GFR (non-indexed)* ≥ 50 mL/min Hepatic Serum total bilirubin ≤ 1.5X ULN OR Direct bilirubin ≤ 1.5X ULN for subjects with total bilirubin levels > 1.5 ULN; ≤ 3X ULN for subjects with hepatoma or Gilbert's disease AST and ALT ≤ 2.5X ULN OR ≤ 5X ULN for subjects with active liver metastases and primary hepatoma Coagulation International normalized ratio (INR) ≤ 1.5X ULN Activated partial thromboplastin time (aPTT) ≤ 1.5X ULN; QTcF < 480 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify